2019
Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE
Zeitler E, Friedman D, Loring Z, Campbell K, Goldstein S, Wegermann Z, Schutz J, Smith N, Black-Maier E, Al-Khatib S, Piccini J. Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. Heart Rhythm 2019, 17: 447-454. PMID: 31561032, PMCID: PMC7519585, DOI: 10.1016/j.hrthm.2019.09.024.Peer-Reviewed Original ResearchConceptsSubcutaneous implantable cardioverter-defibrillatorS-ICD complicationsImplantable cardioverter-defibrillatorS-ICDInappropriate shocksCardioverter-defibrillatorSystem removalLow rate of complicationsProcedure-related complicationsRate of complicationsFood and Drug Administration's ManufacturerManufacturer and User Facility Device ExperienceUser Facility Device ExperiencePatient selectionFollow-upComplicationsTransvenous devicesVentricular fibrillationDevice-device interactionsClinical experiencePatientsDefibrillation failureImplantation techniqueSystem reprogrammingSystem revisionCharacteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)
Goldstein S, Green J, Huber K, Wojdyla D, Lopes R, Alexander J, Vinereanu D, Wallentin L, Granger C, Al-Khatib S. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). The American Journal Of Cardiology 2019, 124: 1406-1412. PMID: 31474328, PMCID: PMC7194994, DOI: 10.1016/j.amjcard.2019.07.046.Peer-Reviewed Original ResearchConceptsThyroid disease historyThyroid diseaseAtrial fibrillationDisease historyThromboembolic eventsClinical outcomesOutcomes of atrial fibrillationHistory of thyroid diseaseBaseline characteristics of patientsCox modelBenefits of apixabanOther Thromboembolic EventsCharacteristics of patientsEffects of anticoagulantsAdjusted hazard ratiosBaseline characteristicsCompare outcomesHazard ratioThyroidApixabanPatientsRandomized treatmentWarfarinHypothyroidismDisease
2018
Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes
Goldstein S, Mentz R, Hellkamp A, Randolph T, Fonarow G, Hernandez A, Yancy C, Al‐Khatib S. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. Clinical Cardiology 2018, 42: 256-263. PMID: 30548280, PMCID: PMC6386168, DOI: 10.1002/clc.23135.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapy implantationCardiac resynchronization therapyHF re-hospitalizationHeart failureRe-hospitalizationHF hospitalizationCardiac resynchronization therapy device implantationOutcome of all-cause mortalityTime of CRT implantationAssociated with clinical outcomesAssociated with similar benefitsAll-cause mortalityAssociated with lower ratesHeart failure patientsCRT implantationResynchronization therapyClinical outcomesHF patientsDevice implantationFailure patientsCenters for MedicarePatientsDelayed implantationReduce mortalityMedicaid Services data
2017
Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes
Goldstein S, Newby L, Cyr D, Neely M, Lüscher T, Brown E, White H, Ohman E, Roe M, Hamm C. Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. Journal Of The American Heart Association 2017, 6: e005334. PMID: 28400368, PMCID: PMC5533023, DOI: 10.1161/jaha.116.005334.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedBiomarkersChi-Square DistributionClopidogrelDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedMultivariate AnalysisNon-ST Elevated Myocardial InfarctionPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProportional Hazards ModelsRisk FactorsTiclopidineTime FactorsTreatment OutcomeTroponinUp-RegulationConceptsNon-ST-segment elevation ACS patientsLong-term ischemic eventsACS patientsDiabetes mellitus prevalenceTroponin levelsBody mass indexStatistically significant heterogeneityGRACE risk scoreHeterogeneity of treatment effectsIschemic eventsIndex ACS eventACS eventsNon-ST-segment elevation ACSMedically managed patientsComposite end pointLong-term outcomesMass indexTreatment effectsRisk scorePeak troponin valuesPercutaneous coronary interventionSignificant heterogeneityStatistically significant differenceManaging patientsPeak troponin
2016
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials
Kragholm K, Goldstein S, Yang Q, Lopes R, Schulte P, Bernacki G, White H, Mahaffey K, Giugliano R, Armstrong P, Harrington R, Tricoci P, Van de Werf F, Alexander J, Alexander K, Newby L. Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials. Circulation 2016, 133: 1560-1573. PMID: 26957532, PMCID: PMC4856566, DOI: 10.1161/circulationaha.115.017299.Peer-Reviewed Original ResearchConceptsIncrease evidence-based careEvidence-based careClinical characteristicsClinical trialsAcute coronary syndrome trialsTranslation of clinical trialNon-ST segment elevation acute coronary syndromeNon-ST segment elevationPhase III clinical trialsPost-myocardial infarction mortalityIII clinical trialsClinical trial enrollmentInfarction mortalityAcute coronary syndromeClinical trial populationsAge strataGeneral populationTrial enrollmentIn-hospitalCoronary syndromeOlder patientsIncreased comorbiditiesTrial backgroundTrial populationEnrollment